

## State of Oklahoma SoonerCare Cotellic<sup>®</sup> (Cobimetinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Pharmacy billing (NDC:		
Dose: Regimen:		
Billing Provider Information		
Provider NPI: Provider Name:		er Name:
Provider Phone: Provider Fax:		vider Fax:
Prescriber Information		
Prescriber NPI:	Prescriber	Name:
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
YesNo B. Is melanoma v C. Will cobimetini D. Will cobimetini YesNo Histiocytic Neopla A. Will cobimetini If answer is none c Additional Information: For Continued Authorizat	Metastatic Melanoma have BRAF V600E or V600H wild-type BRAF? Yes No ib be used as first-line therap ib be used as second-line the asm ib be used as a single agent? of the above, please indicate	y in combination with vemurafenib? Yes No erapy or subsequent therapy with vemurafenib?
3. Has the member experien	ced any adverse drug reaction	e while on cobimetinib therapy? Yes No ons related to cobimetinib therapy? Yes No
Additional Information:		
	tment is medically necessary a	Date: and all information is true and correct to the best of my tion will be requested if necessary.
PLEASE PROVIDE THE INFORMATIO	ON REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma Pharmacy Manage Product Based Prior Fax: 1-800- Phone: 1-800-522	ment Consultants Authorization Unit -224-4014	This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.